EHA 2019: Vemurafenib Plus Rituximab Promising in Relapsed/Refractory Hairy Cell Leukemia
Perhaps best for patients in whom chemotherapy could be dangerous or is not expected to work
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.